Compare Enveric Biosciences Inc (ENVB) vs State Street SPDR Bloomberg High Yield Bond ETF (JNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs State Street SPDR Bloomberg High Yield Bond ETF — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while State Street SPDR Bloomberg High Yield Bond ETF trades at $92.73 (market cap $5.86B). The key difference: State Street SPDR Bloomberg High Yield Bond ETF is far larger — about 861.8× Enveric Biosciences Inc's market cap, and Enveric Biosciences Inc is more actively traded (64,867 versus 7,780,002). Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and State Street SPDR Bloomberg High Yield Bond ETF for 60 Days on average.
| ENVB | JNK | |
|---|---|---|
Market Cap | $6.80M | $5.86B |
Volume | 64,867 | 7,780,002 |
Sector | Health | Fixed Income |
52-Week High | $10.80 | $98.02 |
52-Week Low | $1.27 | $92.30 |
Typical Hold Time | 14 Days | 60 Days |
Enterprise Value | -$1.49M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
JNK trades at $92.76, down 0.13% with a bearish technical outlook. The ETF shows neutral oscillators but bearish moving averages, with key support at $92. Recent dividend distributions of $0.53 provide income, though financial ratios are unavailable. Market sentiment is influenced by rising bond yields and geopolitical tensions affecting high-yield debt markets.
Outlook remains cautious amid elevated Treasury yields and inflation concerns. The high-yield bond sector faces pressure from borrowing costs, though institutional interest persists. Key risks include interest rate volatility and economic slowdown impacting credit quality. Income-focused investors may find value in dividend yield despite market headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →
